icon-account icon-glass

Ultram Withdrawal and Tapering Help

Call us about weaning off ultram   


Looking for Ultram withdrawal treatment? Would you like help getting off Ultram?  Let our nonprofit help you with Ultram Withdrawals. For 15 years we have people in 78 countries Escape Ultram.  Our holistic, natural approach to helping to ease Ultram Side Effects is unmatched. We know how to help Ease Ultram Withdrawals.  Ultram, also known as Tramadol, Ultracet and Ryzolft is a synthetic opioid-like painkiller that also works like an antidepressant. Ultram Withdrawal Symptoms can include worsening anxiety, panic attacks, confusion, delusion, derealization or depersonalization, paranoid thoughts and unusual sensory experiences such as numbness, tingling, prickling and tinnitus. Weaning Ultram is critical to control the symptoms, and at Point of Return we have found that utilizing natural nutraceuticals to help make the symptoms more manageable. We assess individual Ultram Withdrawal rates for each client and set up an at-home program that is right for you. CONTACT our prescription drug experts for a free consultation to get off Tramadol!



ultram withdrawal help  

Our Ultram withdrawal treatment program is a slow taper that allows you to safely step down from Ultram under the guidance of Our Team, Your Physician and Pharmacist. The Pre-Taper is for Symptom Relief. You will not wean  Ultram until you feel better. This is where our Advanced Nutraceuticals are critical. Point of Return provides healthy, Drug-Free Strategies to help ease Ultram withdrawal and support well-being*

Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our In-Home programs are individualized based on your situation. An assessment is done once you start the Ultram Withdrawal Program which allows us to individualize your gameplan based on age; length of time on the medications; health challenges; lifestyle, stress levels; additional medications; and interactions. Don't Wean Ultram alone, work with our Prescription Drug Experts.

Imagine being Free of Ultram Dependency 

- Proven Withdrawal Program completed In-Home with Expert Guidance

- Slowly Wean off Ultram

- All-Natural Nutraceuticals to help Ease Ultram Withdrawal

- Professional information on interactions

- Free Mentoring on our 24/7 private Discussion Board

- Free Assessment Upon Starting our Program (a $400 value)

Enter Discount Code ADFree for FREE Ground Shipping on your Withdrawal Program *USA & Canada Only




Karole - ultram withdrawal

"For me this program was an obsession. It worked a miracle in my life! This program is the best out there and it covers everything. I am FREE and I got my TESTIMONY back! Thank you from the bottom of my heart!" More...

Karole - Ultram Withdrawal Success Story

Kristin - Ultram withdrawal treatment

"The last piece of my 4-piece puzzle was answered by the Point of Return program. God bless your hearts. Point of Return Rocks!!" More...

Kristin - Ultram Withdrawal Success Story

                          using a Natural Approach

Ultram withdrawal team

Our team has survived psychoactive drug withdrawal. More...

Get Ultram withdrawal treatment anywhere in the world

We've helped people in 78 countries and in every state of the USA. More...

Ultram withdrawal media coverage

We have extensive media coverage; television, print, radio. More...


Message sent, thanks!

Ultram Resource Center 





      Ultram Info and History 

      In 1995 Ultram (Tramadol) was released in the United States and used primarily as a pain reliever for acute and chronic pain. While Ultram was initially considered to have a low abuse potential, it was popular in China since the early 1990s, particularly for opiate addicts. Studies have shows that Ultram does have a high risk potential for addiction.

      Ultram can cause physical dependence and a withdrawal syndrome with symptoms associated with SSRI withdrawal, including numbness, anxiety, tingling, tinnitus, stomach upset, insomnia and many others. Symptoms generally surface 12-20 hours after the last dose but this can vary depending on drug metabolism. Ultram withdrawals last longer than those of opiates and follow the withdrawal syndrome length of antidepressants.

      Ultram was isolated from the root bark of N. latifolia, an African medical plant and synthesized into a chemical structure similar to Effexor, an SNRI (Serotonin-Norepinephrine Reuptake Inhibitor).  Ultram can be associated with Serotonin Syndrome, a serious condition caused by excess Serotonin activity. As a result, Ultram should never be combined with St. John’s Wort, 5HTP, Antidepressants or any other item that increases Serotonin. Alcohol should not be consumed while taking Ultram.

      Ultram has a relatively short half-life that helps to explain the severity of the withdrawals frequently experienced by patients.  Ultram should be tapered slowly to minimize withdrawal symptoms.

      Ultram Withdrawal Symptoms, Side Effects, Adverse Reactions


      abdomnial cramping, anxiety, backache, diarrhea, insomnia, chills, irritability, joint pain, muscle pain, vomiting, weakness, perspiration, nausea, increased heart rate, increased blood pressure, confusion, hallucination, numbness, panic attacks, paranoia, tingling


      vertigo, nausea, constipation, headache, somnolence, vomitting, cns stimulation, sweating, dry mouth, insomnia, menstrual issues, sinusitis, cough, rash


      Severe: visual impairment, hepatic failure, pancreatitis, GI bleeding, bradycardia, serotonin syndrome, seizures, suicidal ideation, Stevens-Johnson syndrome, toxic epidermal necrolysis, proteinuria, cholecystitis, hearing loss, myocardial infarction, pulmonary embolism, pulmonary edema, torsade de pointes, bronchospasm, anaphylactoid reactions, angioedema, fetal death, neonatal opioid withdrawal syndrome, SIADH

      Moderate: constipation, euphoria, hallucinations, orthostatic hypotension, peripheral vasodilation, hypertension, hypertonia, depression, dyspnea , urinary retention, hyperglycemia, peripheral edema, hot flashes, blurred vision, confusion, withdrawal , dysphagia, hepatitis, stomatitis, hypotension, amnesia, ataxia, impaired cognition, migraine, dysuria, hematuria, cystitis, anemia, thrombocytopenia, elevated hepatic enzymes, cholelithiasis, cataracts, impotence (erectile dysfunction), palpitations, sinus tachycardia, gout, QT prolongation, dysphonia, respiratory depression, physiological dependence, psychological dependence , hyponatremia, infertility, adrenocortical insufficiency

      Mild: nausea, vertigo, dizziness, headache, drowsiness, vomiting, flushing, agitation, tremor, anxiety, emotional liability, xerostomia, dyspepsia, asthenia, pruritus, insomnia, diarrhea, diaphoresis, anorexia, arthralgia, malaise, syncope, paresthesias, increased urinary frequency, infection, fever, weight loss, myalgia, flatulence, abdominal pain, fatigue, weakness, lethargy, sneezing, nasal congestion, rhinorrhea, cough, hypoesthesia, miosis, restlessness, rash, chills , rhinitis, pharyngitis, sinusitis, influenza, back pain, gastroesophageal reflux, yawning, hyperkinesis, night sweats, irritability, pallor, urticaria, menstrual irregularity , tinnitus, libido decrease, ecchymosis, muscle cramps, gonadal suppression, amenorrhea


      Accidental exposure, acute intoxication of CNS depressants, ethanol ingestion, ethanol intoxication, potential for overdose or poisoning
      Use of tramadol is associated with a significant potential for overdose or poisoning. Tramadol in excessive doses, either alone or in combination with other CNS depressants such as alcohol, is a major cause of drug-related deaths. Fatalities within the first hour of overdosage are not uncommon. Many of the tramadol-related deaths have occurred in patients with previous histories of emotional disturbances or suicidal ideation or attempts, as well as histories of misuse of tranquilizers, alcohol, and other CNS-active drugs. Some deaths have occurred as a consequence of the accidental ingestion of excessive quantities of tramadol alone or in combination with other drugs. Tramadol should be kept out of the reach of pediatric patients, others for whom the drug was not prescribed, and pets as accidental exposure or improper use may cause respiratory failure and a fatal overdose. The use of immediate-release tramadol, tramadol orally disintegrating tablets (Rybix), and extended-release tablets (specifically Ultram ER and generic equivalents) is contraindicated in cases of acute intoxication of CNS depressants including ethanol intoxication and/or intoxication with opiate agonists, hypnotics, centrally-acting analgesics, or psychotropic drugs. Note that while Ryzolt extended-release tablets (and generic equivalents) and extended-release capsules are not specifically contraindicated, use during acute intoxication is not recommended. Tramadol may worsen central nervous system depression and decrease the respiratory rate in these patients. Tell patients not to exceed the recommended tramadol dose and to avoid ethanol ingestion during tramadol therapy. Advise patients of the additive depressant effects of tramadol and alcohol.

      Asthma, coadministration with other CNS depressants, respiratory depression
      As with other opioid agonists, tramadol should be avoided in patients with severe pulmonary disease. Additionally, avoid coadministration with other CNS depressants unless no other alternatives are available, as this significantly increases the risk for respiratory depression, low blood pressure, and death. As tramadol use is contraindicated in any situation where opioid agonist are contraindicated, do not use in patients with severe respiratory depression. Further, the manufacturers of dual-matrix extended-release tablets (e.g., Ryzolt) and extended-release capsules (e.g., ConZip) specifically contraindicate use in patients with acute or severe asthma or hypercapnia in unmonitored care settings or in the absence of resuscitate equipment. Consider alternative non-opioid analgesics instead of tramadol. Respiratory depression is possible with large doses of tramadol, especially when given concurrently with ethanol and anesthetic agents. Concurrent administration with other respiratory depressants exacerbates this risk. If respiratory depression occurs, treat as an overdose; however, administer naloxone cautiously in these situations due to an increased risk of seizures.

      Alcoholism, depression, substance abuse, suicidal ideation
      Do not prescribe tramadol for patients who have depression, suicidal ideation, or addiction problems such as patients with alcoholism. Consider use of non-narcotic analgesics in these patients. Tramadol is an opioid agonist and therefore has abuse potential and risk of fatal overdose from respiratory failure. Addiction may occur in patients who obtain tramadol illicitly or in those appropriately prescribed the drug. The risk of addiction in any individual is unknown. However, patients with mental illness (e.g., major depression) or a family history of substance abuse (including alcoholism) have an increased risk of opioid abuse. Assess patients for risks of addiction, abuse, or misuse before drug initiation, and monitor patients who receive opioids routinely for development of these behaviors or conditions. A potential risk of abuse should not preclude appropriate pain management in any patient, but requires more intensive counseling and monitoring. Abuse and addiction are separate and distinct from physical dependence and tolerance; patients with addiction may not exhibit tolerance and symptoms of physical dependence. The misuse of tramadol extended-release tablets or extended-release capsules by splitting, breaking, crushing, chewing, snorting, or injecting the dissolved product will result in the uncontrolled delivery and can result in overdose and death. To discourage abuse, the smallest appropriate quantity of tramadol should be dispensed, and proper disposal instructions for unused drug should be given to patients.

      Ultram References and Information 

      According to the FDA:
      Discontinuation of Treatment
      Withdrawal symptoms may occur if tramadol hydrochloride extended-release capsules is discontinued abruptly. Clinical experience with tramadol suggests that withdrawal symptoms may be reduced by tapering tramadol hydrochloride extended-release capsules [see WARNINGS AND PRECAUTIONS (5.10) and DRUG ABUSE AND DEPENDENCE ( 9.3)].

      Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Physical dependence is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist.







      *While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.

      *The statements/info on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.

      * Testimonial results may vary person to person.

      *The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized With Your physician to help you with your drug withdrawal process and with his or her consent and support throughout.

      *This program is not meant to cure or prevent any disease or illness.

      *Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support throughout the process. More..